We are also the first group to comprehensively investigate the therapeutic effects of crizotinib in NSCLC patients with different ALK fusion patterns and demonstrated that the complex ALK fusions were associated with improved post-ALK TKI patient survival. The gene discussed is ALK; the disease is non-small cell lung carcinoma.